Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Nov 30, 2023
Trial Information
Current as of July 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how changes in the bacteria living in the body, known as dysbiosis, may affect the immune response in infants with bronchiolitis, a common lung infection caused mainly by the respiratory syncytial virus (RSV). The study will involve 80 children under the age of 2 who have been hospitalized or treated for bronchiolitis during the RSV season. Researchers will collect samples from the mouth, nose, and stool to look for imbalances in the bacteria, as well as a small blood sample to assess the immune system's reaction.
To participate, infants must be under 12 months old and diagnosed with bronchiolitis during RSV season, with no history of chronic illnesses or previous bronchiolitis. Parents or guardians will need to provide consent for their child to join. Participants can expect to provide samples during their hospital stay or clinic visit, and their contributions will help improve our understanding of how to better predict and manage bronchiolitis in young children.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Infants \<12 months
- • With bronchiolitis during RSV epidemic season
- • No chronic illness
- • No bronchiolitis medical history
- • Signed consent from parents or legal guardians
- Exclusion Criteria:
- • Chronic respiratory illness
- • Medical history of bronchiolitis or newborn asthma
- • Treatment with immunosuppressants
- • Patient with no social security affiliation
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Clamart, , France
Garches, , France
Paris, , France
Patients applied
Trial Officials
Etienne BIZOT, Doctor
Principal Investigator
AP-HP Hôpital Antoine Beclere
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported